Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of South Florida |
---|---|
Information provided by: | University of South Florida |
ClinicalTrials.gov Identifier: | NCT00584025 |
The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinson's disease patients who have been optimized on antiparkinsonian medication. The secondary objective is to study the effect of intravenous LEV on additional motor and cognitive symptoms of PD.
Condition | Intervention | Phase |
---|---|---|
Parkinson's Disease |
Drug: levetiracetam Drug: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment |
Estimated Enrollment: | 20 |
Study Start Date: | December 2007 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Keppra IV
|
Drug: levetiracetam
100 - 500mg IV q 15 min
|
2: Placebo Comparator
Placebo
|
Drug: Placebo
Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
|
Ages Eligible for Study: | 30 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
University of South Florida | |
Tampa, Florida, United States, 33612 |
Principal Investigator: | Theresa A Zesiewicz, MD | University of South Florida |
Responsible Party: | University of South Florida ( Theresa Zesiewicz, MD ) |
Study ID Numbers: | 5 |
Study First Received: | December 21, 2007 |
Last Updated: | June 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00584025 |
Health Authority: | United States: Institutional Review Board |
Parkinson's disease dyskinesia levetiracetam keppra |
Ganglion Cysts Movement Disorders Parkinson Disease Basal Ganglia Diseases Central Nervous System Diseases |
Etiracetam Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases Dyskinesias |
Nootropic Agents Therapeutic Uses Nervous System Diseases |
Central Nervous System Agents Pharmacologic Actions Anticonvulsants |